日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

The Effect of Lacticaseibacillus paracasei LPC100 and Lactiplantibacillus plantarum LP140 on Bone Mineral Density in Postmenopausal Women: A Multicenter, Randomized, Placebo-Controlled Study

乳酸杆菌副干酪菌株LPC100和植物乳杆菌LP140对绝经后妇女骨密度的影响：一项多中心、随机、安慰剂对照研究

期刊:Journal of Clinical Medicine
影响因子:2.9
doi:10.3390/jcm13195977
Głogowska-Szeląg, Joanna; Palka-Kisielowska, Ilona; Porawska, Wiesława; Bierła, Joanna B; Szczepankowska, Agnieszka K; Aleksandrzak-Piekarczyk, Tamara; Cukrowska, Bożena
发表日期：2024
文献求助 收藏

FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension

FKB327（一种阿达木单抗生物类似药）与参考产品：一项随机、III期、双盲研究及其开放标签扩展研究的结果

期刊:Arthritis Research & Therapy
影响因子:4.6
doi:10.1186/s13075-019-2046-0
Genovese, Mark C; Glover, Josephine; Greenwald, Maria; Porawska, Wieslawa; El Khouri, Elias Chalouhi; Dokoupilova, Eva; Vargas, Juan Ignacio; Stanislavchuk, Mykola; Kellner, Herbert; Baranova, Elena; Matsunaga, Nobuhito; Alten, Rieke
发表日期：2019
文献求助 收藏

Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study

在类风湿性关节炎患者中，从原研英夫利昔单抗换用生物类似药SB2与继续使用原研英夫利昔单抗和SB2相比，其安全性、免疫原性和疗效：一项随机、双盲、III期过渡研究的结果

期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1136/annrheumdis-2017-211741
Smolen, Josef S; Choe, Jung-Yoon; Prodanovic, Nenad; Niebrzydowski, Jaroslaw; Staykov, Ivan; Dokoupilova, Eva; Baranauskaite, Asta; Yatsyshyn, Roman; Mekic, Mevludin; Porawska, Wieslawa; Ciferska, Hana; Jedrychowicz-Rosiak, Krystyna; Zielinska, Agnieszka; Lee, Younju; Rho, Young Hee
关节炎
免疫/内分泌
发表日期：2018
文献求助 收藏

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy

一项 III 期随机、双盲、平行组研究，比较 SB4 与依那西普参考产品在接受甲氨蝶呤治疗后仍患有活动性类风湿关节炎的患者中的疗效。

期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1136/annrheumdis-2015-207588
Emery, Paul; Vencovský, Jiří; Sylwestrzak, Anna; Leszczyński, Piotr; Porawska, Wieslawa; Baranauskaite, Asta; Tseluyko, Vira; Zhdan, Vyacheslav M; Stasiuk, Barbara; Milasiene, Roma; Barrera Rodriguez, Aaron Alejandro; Cheong, Soo Yeon; Ghil, Jeehoon
关节炎
发表日期：2017
文献求助 收藏

A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy

一项随机、双盲、III期研究比较了英夫利昔单抗生物类似药SB2与英夫利昔单抗参考产品Remicade在接受甲氨蝶呤治疗后仍患有中重度类风湿性关节炎的患者中的疗效。

期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1136/annrheumdis-2015-207764
Choe, Jung-Yoon; Prodanovic, Nenad; Niebrzydowski, Jaroslaw; Staykov, Ivan; Dokoupilova, Eva; Baranauskaite, Asta; Yatsyshyn, Roman; Mekic, Mevludin; Porawska, Wieskawa; Ciferska, Hana; Jedrychowicz-Rosiak, Krystyna; Zielinska, Agnieszka; Choi, Jasmine; Rho, Young Hee; Smolen, Josef S
关节炎
发表日期：2017
文献求助 收藏

Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4

SB4 治疗类风湿性关节炎患者的长期疗效和安全性，包括继续接受 SB4 治疗或从参考依那西普疗法转换为 SB4 治疗的患者。

期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1136/annrheumdis-2017-211591
Emery, Paul; Vencovský, Jiří; Sylwestrzak, Anna; Leszczyński, Piotr; Porawska, Wieslawa; Stasiuk, Barbara; Hilt, Joanna; Mosterova, Zdenka; Cheong, Soo Yeon; Ghil, Jeehoon
关节炎
发表日期：2017
文献求助 收藏

Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results

一项为期 54 周的双盲试验比较了生物类似药 SB2 与参考药物英夫利昔单抗：临床、结构和安全性结果

期刊:Rheumatology
影响因子:4.4
doi:10.1093/rheumatology/kex254
Smolen, Josef S; Choe, Jung-Yoon; Prodanovic, Nenad; Niebrzydowski, Jaroslaw; Staykov, Ivan; Dokoupilova, Eva; Baranauskaite, Asta; Yatsyshyn, Roman; Mekic, Mevludin; Porawska, Wieskawa; Ciferska, Hana; Jedrychowicz-Rosiak, Krystyna; Zielinska, Agnieszka; Choi, Jasmine; Rho, Young Hee
发表日期：2017
文献求助 收藏

Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate

皮下注射阿巴西普与静脉注射阿巴西普：一项针对甲氨蝶呤疗效不佳患者的IIIb期非劣效性研究

期刊:
影响因子:
doi:10.1002/art.30463
Genovese, M C; Covarrubias, A; Leon, G; Mysler, E; Keiserman, M; Valente, R; Nash, P; Simon-Campos, J A; Porawska, W; Box, J; Legerton, C 3rd; Nasonov, E; Durez, P; Aranda, R; Pappu, R; Delaet, I; Teng, J; Alten, R
发表日期：2011
文献求助 收藏